MT-4

CAS No. 2327925-35-7

MT-4( —— )

Catalog No. M33223 CAS No. 2327925-35-7

MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 88 Get Quote
5MG 141 Get Quote
10MG 226 Get Quote
25MG 365 Get Quote
50MG 522 Get Quote
100MG 691 Get Quote
500MG 1386 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    MT-4
  • Note
    Research use only, not for human use.
  • Brief Description
    MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum.
  • Description
    MT-4 blocks the TG2/FN complex at the interface between cancer cells and the tumor niche. MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2327925-35-7
  • Formula Weight
    361.44
  • Molecular Formula
    C21H23N5O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (276.67 mM; Ultrasonic )
  • SMILES
    CN(C)c1cc(C)nc(Nc2ccc(NC(=O)Cc3ccccc3)cc2)n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Sima LE, et al. Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin. Mol Cancer Ther. 2019 Jun;18(6):1057-1068.?
molnova catalog
related products
  • Labetuzumab

    Labetuzumab is a humanized anti-carcinoembryonic antigen (CEA) monoclonal antibody with anticancer activity that inhibits tumor growth and is used in the study of thyroid and colorectal cancer (CRC).

  • Metamorphosin A

    Metamorphosin A

  • Boeravinone B

    Boeravinone B, a novel efflux pump inhibitor, apart from inhibiting the MdeA mediated efflux, also significantly inhibit the biofilm formation of S. aureus, boeravinone B may be used in combination with mupirocin for further development.